The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
|Videos|October 21, 2017
Dr. Schadendorf on the Efficacy of Targeted Therapy Plus Checkpoint Inhibitors
Author(s)Dirk Schadendorf, MD
Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.
Advertisement
Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses the efficacy of combining targeted therapy with checkpoint inhibitors for patients with melanoma.
There has been great progress in treating advanced melanoma, states Schadendorf. Checkpoint blockade has made contributions, giving long duration of responses and a median overall survivial of 3 years.
Advertisement
Related to this article
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
Revisit Every OncLive On Air Episode From June 2026
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
5